Isotretinoin - Nova BioPharma

Drug Profile

Isotretinoin - Nova BioPharma

Alternative Names: 13 cis retinoic acid; 13-CRA

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nova Biopharma
  • Class Antiacnes; Antineoplastics; Keratolytics; Retinoids
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neuroblastoma

Most Recent Events

  • 04 Oct 2017 Preclinical trials in Neuroblastoma in India before October 2017 (PO, Capsule)
  • 04 Oct 2017 Preclinical trials in Neuroblastoma in India before October 2017 (PO, Liquid)
  • 04 Oct 2017 Nova BioPharma plans the My-CRA phase I/II trial for Neuroblastoma(In children, In adolescents, In adults) (NCT03291080)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top